Pacira Pharmaceuticals Inc-DE
Затворен
СекторЗдравеопазване
23.83 1.02
Преглед
Промяна на цената на акция
24 ч
Минимум
23.4
Максимум
24.18
Приходи | 1.3M 2.9M |
|---|---|
Продажби | -19M 177M |
P/E Средно за сектора | 174.692 50.958 |
EPS | 0.6 |
Марж на печалбата | 1.644 |
Служители | 825 |
EBITDA | 5M 30M |
Препоръки | Купи |
|---|---|
12-месечна прогноза | +26.54% upside |
Следващи печалби | 4.08.2026 г. |
|---|
Пазарна капитализация | -206M 894M |
|---|---|
Предишно отваряне | 22.81 |
Предишно затваряне | 23.83 |
Настроения в новините
By Acuity
67%
33%
295 / 342 Класиране в Healthcare
Pacira Pharmaceuticals Inc-DE Графика
Миналото представяне не гарантира бъдещи резултати.
Относно Pacira Pharmaceuticals Inc-DE
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.